{
	"kja6j8p6Text": "Ja<span class=\"_ _c\"></span>cob<span class=\"_ _c\"></span>sen P<span class=\"_ _c\"></span>L et al. 2<span class=\"_ _c\"></span>0<span class=\"_ _c\"></span>1<span class=\"_ _23\"></span>5b<span class=\"_ _23\"></span><span class=\"fs1 v1\">1</span>",
	"kja6j8p7Text": "A randomised,<span class=\"_ _0\"></span> double-<span class=\"_ _0\"></span>blind s<span class=\"_ _0\"></span>tudy of<span class=\"_ _0\"></span> Brintellix® vs<span class=\"_ _0\"></span>. escilatopram on<span class=\"_ _0\"></span> sexual func<span class=\"_ _0\"></span>tioning <br><span class=\"ls17 ws25\">in patient<span class=\"_ _0\"></span>s wi<span class=\"_ _0\"></span>th major depressi<span class=\"_ _0\"></span>ve disorder (<span class=\"_ _2\"></span>MDD<span class=\"_ _c\"></span>)<span class=\"_ _0\"></span> experiencing treatment-emergent <br><span class=\"ls1 ws8f\">s<span class=\"_ _0\"></span>exual dysf<span class=\"_ _0\"></span>unc<span class=\"_ _0\"></span>tion.</span></span>",
	"kja6j8p8Text": "Study objective: <span class=\"ff3\">Compar<span class=\"_ _2\"></span>e the effects of Brintellix® vs. escitalopr<span class=\"_ _2\"></span>am on sexual functioning in <br>adults with well-trea<span class=\"_ _2\"></span>ted major depressive disor<span class=\"_ _2\"></span>der experiencing SSRI-induced sexual dysfunction.</span>",
	"kja6j8p9Text": "Key inclusion criteria<br><span class=\"ff3\">Men or women aged 18–55 years</span>",
	"kja6j8paText": "On a stable (at least eight weeks) SSRI  tr<span class=\"_ _2\"></span>eatment <br>regimen for a major depressive episode (MDE)",
	"kja6j8pbText": "T<span class=\"_ _c\"></span>reated with,<span class=\"_ _c\"></span> and responding to, monotherapy with <br>citalopram,<span class=\"_ _2\"></span> paroxetine,<span class=\"_ _c\"></span> or sertraline",
	"kja6j8pcText": "CGI-S scores of 3 or less at screening and baseline visits",
	"kja6j8pdText": "Sexually active at least every two weeks befor<span class=\"_ _2\"></span>e onset of<span class=\"_ _0\"></span> <br>the current MDE and/or SSRI use and experiencing <br>symptoms of sexual dysfunction attributed to <br>current SSRI treatment",
	"kja6j8peText": "T<span class=\"_ _3\"></span>otal score of<span class=\"_ _0\"></span> 41 or less for women and 47 or <br>less for men on the CSFQ-14",
	"kja6j8pfText": "Eight weeks of",
	"kja6j8pgText": "treatment followed",
	"kja6j8phText": "by 12-week safety",
	"kja6j8piText": "follow-up",
	"kja6j8pjText": "Back",
	"kja6j8pkText": "MDE, maj<span class=\"_ _2\"></span>or depressiv<span class=\"_ _2\"></span>e episode<span class=\"_ _c\"></span>; CSFQ-<span class=\"_ _2\"></span>1<span class=\"_ _c\"></span>4, Change in S<span class=\"_ _2\"></span>exual F<span class=\"_ _c\"></span>unc<span class=\"_ _0\"></span>tioning Qu<span class=\"_ _2\"></span>estionnair<span class=\"_ _2\"></span>e Short-Form<span class=\"_ _2\"></span>; MADRS, Montg<span class=\"_ _2\"></span>omery-Åsberg Depressio<span class=\"_ _2\"></span>n Rating Scale<span class=\"_ _c\"></span>; CGI, Clin<span class=\"_ _2\"></span>ical <br>Global I<span class=\"_ _2\"></span>mpression<span class=\"_ _c\"></span>; POMS-brief, Pr<span class=\"_ _2\"></span>ofile of Moo<span class=\"_ _2\"></span>d States brief fo<span class=\"_ _2\"></span>rm.",
	"kja6j8plText": "Primary outcome: <span class=\"ff3 ls36 wsb\">Cha<span class=\"_ _2\"></span>nge fro<span class=\"_ _2\"></span>m base<span class=\"_ _2\"></span>line i<span class=\"_ _c\"></span>n the CSFQ-<br>1<span class=\"_ _c\"></span>4 total sc<span class=\"_ _2\"></span>ore a<span class=\"_ _2\"></span>f<span class=\"_ _0\"></span>ter ei<span class=\"_ _2\"></span>ght w<span class=\"_ _2\"></span>eeks of tr<span class=\"_ _2\"></span>eatme<span class=\"_ _2\"></span>nt.</span>",
	"kja6j8pmText": "Secondary ou<span class=\"_ _0\"></span>tcomes: <span class=\"ff3 ls36 wsb\">The MADR<span class=\"_ _2\"></span>S, C<span class=\"_ _2\"></span>GI, an<span class=\"_ _2\"></span>d POMS-bri<span class=\"_ _2\"></span>ef wer<span class=\"_ _2\"></span>e <br>used to a<span class=\"_ _2\"></span>ssess antid<span class=\"_ _2\"></span>epr<span class=\"_ _2\"></span>essant efficacy<span class=\"_ _2\"></span>. Safety was assessed v<span class=\"_ _2\"></span>ia <br>adv<span class=\"_ _2\"></span>erse ev<span class=\"_ _2\"></span>ents, vital si<span class=\"_ _2\"></span>gns, el<span class=\"_ _2\"></span>ectrocardi<span class=\"_ _2\"></span>ogram<span class=\"_ _2\"></span>s, lab<span class=\"_ _2\"></span>orato<span class=\"_ _2\"></span>r<span class=\"_ _0\"></span>y val<span class=\"_ _2\"></span>ues, <br><span class=\"ls37 ws7d\">weight, and<span class=\"_ _0\"></span> physic<span class=\"_ _0\"></span>al examinat<span class=\"_ _0\"></span>ion finding<span class=\"_ _0\"></span>s.</span></span>",
	"kja6j8pnText": "Brintellix® 10 – 20 mg (n=225)",
	"kja6j8poText": "Escitalopram (n=222)",
	"kja6j8ppText": "Eight-week double-blind treatment period",
	"Brintellix_876bd9f614": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_871e32a93e": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span> Jacobsen PL et al. J Sex Med 2015;12:2036–2048.</div>"
}
